[🇵🇰] Medical and Hospital facilities

[ghazi]

Pakistan’s Maple Leaf Cement subsidiary to construct $110mn hospital in Islamabad​

BR

Novacare Hospitals (Private) Limited, a subsidiary of Maple Leaf Cement Factory Limited (MLCF), will construct a $110 million state-of-the-art hospital in Islamabad.

The development was shared by MLCF in a notice to the Pakistan Stock Exchange (PSX) on Monday.

“Novacare Hospitals (Private) Limited, a wholly-owned subsidiary of the company, will start constructing a state-of-the-art hospital in Islamabad, and has signed an international affiliation agreement with Imperial College Healthcare NHS Trust, a leading UK teaching hospital group,” read the notice.

MLCF in its notice shared that the total investment in the project will be $110 million, and the hospital will be located on a 50-Kanal plot in DHA Phase-V, Islamabad.

“The 250-bed hospital will have a covered area of 550,000 square feet and will provide comprehensive tertiary healthcare across 28 clinical services,” it added.

MLCF shared that the hospital is being designed by HKS Inc., a US-based global design firm.

“As a result of its affiliation with Imperial College Healthcare, Novacare will benefit from the expertise of a leading UK teaching hospital group. Novacare will gain expert advisory input from Imperial College Healthcare on models of care, services, and staffing, and aims to implement their clinical standards and protocols.

 

[Ghazi52]

Two hospitals near completion in Pindi​

Construction of both hospitals ends; procurement of medical equipment underway

Correspondent
September 15, 2024

RAWALPINDI: Two major hospitals, one located near Rawat and the other at Jorian Chakri in Rawalpindi district, are nearing completion.

These hospitals, initiated during the previous government, have now reached their final stages of development, with preparations underway for their operational launch.

The Rawat Pothohar Town Tehsil Headquarters Hospital, designed to accommodate 100 beds, and the Jorian Chakri Road Hospital, with a capacity of 60 beds, together have an estimated cost exceeding Rs1.4 billion.

Construction of both hospital buildings has been completed, and the procurement process for medical equipment is underway. Final finishing touches are expected to begin next month. The foundation stone for these projects was laid by former federal minister Ghulam Sarwar Khan.

 

[Ghazi52]

Layyah Hospital, Punjab.

 

[Ghazi52]

In a major step towards strengthening social protection for residents, Chief Minister Ali Amin Gandapur has announced plans to add life insurance to the Sehat Card Plus program.

The decision came during a meeting aimed at enhancing the healthcare initiative, reflecting the government's commitment to providing more comprehensive support to its people.

 

[Ghazi52]

Construction work in progress at Shaukat Khanum Cancer Hospital Karachi.

 

[Ghazi52]

Nawaz Sharif Institute of Cardiology Sargodha being constructed at full speed. First of its kind in Sargodha division.

 

[Ghazi52]

Manufacturing HIV drug in Pakistan: Ferozsons partners with US-based Gilead​

BR Web Desk
October 3, 2024

Ferozsons Laboratories Limited (Ferozsons), a Pakistani pharmaceutical company, has entered into a non-exclusive voluntary license agreement with Gilead Sciences Ireland UC, a US-based biopharmaceutical company, for the manufacture and sale of licensed generic lenacapavir.

The listed company shared the development in a notice to the Pakistan Stock Exchange (PSX) on Thursday.

Ferozsons informed that it is one of six global partners to have signed a voluntary license agreement with Gilead to produce high-quality generic of lenacapavir.

“Lenacapavir is approved by US FDA [Food and Drug Administration] for infection caused by the human immunodeficiency virus (HIV) for heavily treatment-experienced patients (HTE), and is being investigated for use in HIV prevention,” said the company.

The agreement covers lenacapavir for HIV prevention (pending approval), in addition to the approved indication of HIV treatment in heavily treatment-experienced (HTE) adults with multi-drug resistant HIV.

The use of lenacapavir for HIV prevention is investigational and the safety and efficacy of lenacapavir for this use have not been established, said the company.

“Under this non-exclusive license, Ferozsons or its affiliates can manufacture and sell, subject to required regulatory approvals, its licensed generic of Gilead proprietary compound Lenacapavir in 120 (one hundred twenty) primarily low and lower- middle-income countries.

“Under the licensing agreement, the company has a right to receive a technology transfer of the Gilead manufacturing process for lenacapavir to enable it to scale up production,” read the statement.

Ferozsons shared that Lenacapavir is available in two dosage forms: (a) an injectable drug product in a vial kit configuration containing 309 mg/mL Lenacapavir, or, (b) an oral tablet drug product containing 300mg of Lenacapavir.

“The injectable drug product will be manufactured at Ferozsons’ JV Subsidiary, BF Biosciences Limited (BFBIO), while the oral variant will be manufactured at Ferozsons’ oral solid dosage (OSD) facility.